Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing

26 Oct 2013

Abstract excerpt

OBJECTIVE: To examine potential performance of screening for trisomies by cell-free (cf) DNA testing in maternal blood contingent on results of first-line testing by combinations of fetal translucency thickness (NT), fetal heart rate (FHR), ductus venosus pulsatility index (DV PIV), and serum-free β-human chorionic gonadotropin (β-hCG), pregnancy-associated plasma protein-A (PAPP-A), placental growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24192489
DOI: 10.1159/000356066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA TestingPMID 24192489Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingSemantic proximity Read ↗

First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical TestingSemantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Routine first‐trimester screening for fetal trisomies in twin pregnancy: cell‐free DNA test contingent on results from combined testSemantic proximity Read ↗

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studySemantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

Analysis of cell‐free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13Semantic proximity Read ↗

Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal AbnormalitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.